Regulations.gov document
Letter from FDA OC to Vanda Pharmaceuticals Inc. and FDA CDER
Other · FDA-2022-N-2390 · posted Oct 15, 2025
Key facts
| Document ID | FDA-2022-N-2390-0584 |
|---|---|
| Title | Letter from FDA OC to Vanda Pharmaceuticals Inc. and FDA CDER |
| Document type | Other |
| Subtype | Letter(s) |
| Agency | FDA |
| Docket | FDA-2022-N-2390 |
| Posted | Oct 15, 2025 |
| Comment period opens | Oct 15, 2025 |
At a glance
- 1–9 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: